Table 1.
Characteristics of NLC formulations.
| Sample | Composition | EE a (%) | DL b | Mean Diameter (nm) | PDI | Z Pot c (mV) | ||
|---|---|---|---|---|---|---|---|---|
| MM (mg) | DXM (mg) | Oil (µL) | ||||||
| F1 | 400 | 10 | 0 | 86.4 ± 3.0 | 21.6 | 152.2 ± 2.8 | 0.24 ± 0.01 | −15.9 ± 1.0 |
| F2 | 400 | 10 | 25 | 97.7 ± 3.1 * | 24.4 | 144.9 + 1.0 * | 0.22 ± 0.01 | −10.4 ± 0.8 |
| F3 | 400 | 10 | 50 | 94.3 ± 2.9 * | 23.6 | 142.1 + 1.9 * | 0.20 ± 0.01 | −9.1 ± 0.4 |
| F4 | 400 | 10 | 100 | 94.2 ± 3.0 * | 23.6 | 145.0 + 0.8 * | 0.20 ± 0.01 | −9.3 ± 1.4 |
The results express the mean ± SD (n = 3). a Encapsulation efficiency. b Drug loading expressed as µg of DXM/mg of MM lipid. c Zeta potential, * p < 0.05 in comparison with F1 (SLNs-DXM).